

# CoNCERT Pharmaceuticals, Inc.

## Corporate Headquarters:

99 Hayden Avenue  
Suite 500  
Lexington, MA 02421  
Tel: 781.860.0045  
[www.concertpharma.com](http://www.concertpharma.com)

**Founded:** April 2006

**Employees:** 44

## Venture Funding:

\$96.4 million YTD  
Series A (May 2006): \$10.0 million  
Series B (Nov 2006): \$48.5 million  
Series C (April 2008): \$37.9 million

## Management Team:

Roger Tung, Ph.D.,  
*Co-Founder, President and CEO*

Steven Bernitz  
*Chief Business Officer*

Nancy Stuart  
*Chief Operating Officer*

Robert Silverman, J.D., Ph.D.  
*General Counsel*

Philip Graham, Ph.D.  
*Vice President, Program and Product Management*

Scott Harbeson, Ph.D.  
*Vice President, Research*

David Wells, Ph.D.  
*Vice President, Pharmacokinetics, Toxicology and Clinical Pharmacology*

Robert Zelle, Ph.D.  
*Vice President, Drug Development*

## Investor and Media Contact:

Justine Koenigsberg  
*Senior Director, Corporate Communications and Investor Relations*  
Tel: 781.674.5284  
[jkoenigsberg@concertpharma.com](mailto:jkoenigsberg@concertpharma.com)

## Business Development Contact:

Jonathan Montagu  
*Director, Business Development*  
Tel: 781.860.0045 ext. 206  
[jmontagu@concertpharma.com](mailto:jmontagu@concertpharma.com)

Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing deuterium, a naturally-occurring element. Deuterium substitution fully retains potency and selectivity, greatly increasing the odds of successful development. Additionally, selective deuterium replacements can improve important drug properties such as bioavailability and metabolism, enabling increased efficacy and tolerability. Concert's improved compounds have the opportunity for independent patents as novel compositions of matter.

The Company's technology is applicable across a wide range of therapeutic areas including, HIV/AIDS, vasomotor symptoms, renal disease, among others. The Company expects to partner certain programs while working to develop other products independently.

Concert's corporate headquarters are located in Lexington, Massachusetts. The Company is led by an experienced management team and Board of Directors, and has been financed by leading venture capitalists and institutional investors.

## Concert's product platform offers:

- Balanced product portfolio modeled from branded and generic drugs;
- Improved, best-in-class compounds derived from existing drugs;
- Novel, differentiated compounds supporting strong IP position;
- Rapid proof-of-concept; and
- Knowledge based approach to reduce R&D risk, time and expense.

## Product Pipeline:

Program	Indication	Lead Identification	Preclinical	Phase I
5HT modulator	Vasomotor symptoms	CTP-347		
Protease inhibitor	HIV	CTP-518		
Anti-inflammatory / anti-fibrotic	Chronic Kidney Disease			
EGFR inhibitor	Oncology			
Prostacyclin analog	PAH			
Kinase inhibitor	Rheumatoid Arthritis			
Oxazolidinone	MRSA infection			

## Board of Directors:

Richard Aldrich  
*Chairman of the Board  
Chairman, RA Capital*

Ronald Barrett, Ph.D.  
*Chief Executive Officer, XenoPort*

Douglas Cole, M.D.  
*General Partner, Flagship Ventures*

Jens Eckstein, Ph.D.  
*General Partner, TVM Capital*

Stephen Hoffman, M.D., Ph.D.  
*Managing Director, Skyline Ventures*

Peter Barton Hutt  
*Senior Counsel, Covington and Burling;  
Former Chief Counsel, FDA*

Wilf Jaeger, M.D.  
*Partner and Founder, Three Arch Partners*

Roger Tung, Ph.D.  
*President and Chief Executive Officer,  
Concert Pharmaceuticals, Inc.*

## Product Advisory Board:

Chuck Finn  
*CEO, RRD International;  
Former SVP, Quintiles*

Eric Gordon  
*Skyline; Former Executive,  
Bristol-Myers Squibb*

Dan Grau  
*CEO and Vice Chair, Cortria  
Former COO, CombinatoRx*

Peter Barton Hutt  
*Covington and Burling;  
Former Chief Counsel, FDA*

Jim O'Shea  
*Former President and CEO, Sepracor*

Tom Salzmann  
*Former EVP, Preclinical Development and  
Global Operations, Merck*

Wendell Wierenga  
*Former SVP, WW Head of R&D,  
Parke-Davis*

## Product Pipeline:

Concert has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas.

Concert's product development candidates include CTP-518, an HIV protease inhibitor, and CTP-347, currently in Phase I testing, as a non-hormonal treatment for vasomotor symptoms in patients with increased risk of adverse effects due to, or contraindicated to using hormone therapy.

## Benefits of Deuterium Substitution:

Deuterium is a naturally-occurring relative of hydrogen that is isolated from seawater. An average human adult has close to 2 grams of deuterium in their body. Deuterium has a long history of use in clinical settings – primarily in pharmacokinetic and metabolism studies to evaluate chemical and biological processes. Deuterium-substituted compounds retain their molecular shape and thus have comparable potency and selectivity with respect to their hydrogen analogs. However, since deuterium is heavier than hydrogen, it forms significantly stronger bonds with carbon. Concert is using this difference to improve adsorption, distribution, metabolism, excretion, and toxicity properties. Improving these properties are important because they limit the potential of many important, currently used medicines, and are a major reason for clinical trial failure of experimental agents.

## Investors:

Concert has a balanced investor base which includes both venture capital and public equity institutional investors.

- Adage Capital Management
- Alexandria Equities, LLC
- Brookside Capital Partners Fund
- Flagship Ventures
- Greylock Partners
- Mediphase Venture Partners
- New Leaf Venture Partners
- Skyline Ventures
- SR One, Ltd.
- Three Arch Partners
- TVM Capital
- Westfield Capital Management

A listing of Concert Pharmaceuticals' shareholders is available online at [www.concertpharma.com](http://www.concertpharma.com).